{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:36:25Z","timestamp":1777887385291,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ymgme.2026.109734","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T16:27:00Z","timestamp":1768235220000},"page":"109734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety profile of idursulfase administered at home in patients with mucopolysaccharidosis II enrolled in the Hunter Outcome Survey"],"prefix":"10.1016","volume":"147","author":[{"given":"Barbara K.","family":"Burton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Guffon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Audi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaco","family":"Botha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.H.","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Muenzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2026.109734_bb0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","article-title":"Epidemiology of mucopolysaccharidoses","volume":"121","author":"Khan","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109734_bb0010","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.ymgme.2026.109734_bb0015","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","article-title":"Initial report from the Hunter Outcome Survey","volume":"10","author":"Wraith","year":"2008","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2026.109734_bb0020","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3390\/ijms21041258","article-title":"Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment","volume":"21","author":"D'Avanzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2026.109734_bb0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/diagnostics11020273","article-title":"Epidemiology of mucopolysaccharidoses update","volume":"11","author":"Celik","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ymgme.2026.109734_bb0030","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00431-012-1703-y","article-title":"Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls","volume":"171","author":"Burton","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2026.109734_bb0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.36469\/jheor.2022.33801","article-title":"Clinical characteristics and healthcare resource utilization for patients with mucopolysaccharidosis II (MPS II) in the United States: a retrospective chart review","volume":"9","author":"Ayodele","year":"2022","journal-title":"J. Health Econ. Outcomes Res."},{"key":"10.1016\/j.ymgme.2026.109734_bb0040","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10545-017-0075-x","article-title":"Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS)","volume":"40","author":"Burton","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.109734_bb0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13023-017-0712-3","article-title":"Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the Hunter Outcome Survey (HOS)","volume":"12","author":"Muenzer","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.109734_bb0050","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2019.07.016","article-title":"Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England","volume":"129","author":"Broomfield","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109734_bb0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2026.109734_bb0060","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2026.109734_bb0065","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/DDDT.S139601","article-title":"Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future","volume":"11","author":"Whiteman","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2026.109734_bb0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-6-72","article-title":"Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease","volume":"6","author":"Scarpa","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.109734_bb0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1590\/S1415-47572014000300003","article-title":"Guidelines for diagnosis and treatment of Hunter syndrome for clinicians in Latin America","volume":"37","author":"Giugliani","year":"2014","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.ymgme.2026.109734_bb0080","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1542\/peds.2008-0999","article-title":"Multidisciplinary management of Hunter syndrome","volume":"124","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2026.109734_bb0085","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00431-011-1606-3","article-title":"The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus","volume":"171","author":"Muenzer","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2026.109734_bb0090","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41436-020-0909-z","article-title":"Treatment of mucopolysaccharidosis type II (Hunter syndrome): a Delphi derived practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"22","author":"McBride","year":"2020","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2026.109734_bb0095","author":"FDA"},{"key":"10.1016\/j.ymgme.2026.109734_bb0100","author":"EMA"},{"key":"10.1016\/j.ymgme.2026.109734_bb0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ymgme.2010.06.011","article-title":"Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey","volume":"101","author":"Burton","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109734_bb0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1824-7288-39-53","article-title":"Home treatment in paediatric patients with Hunter syndrome: the first Italian experience","volume":"39","author":"Ceravolo","year":"2013","journal-title":"Ital. J. Pediatr."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2026.109734_bb0115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10198-016-0787-0","article-title":"Social\/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe","volume":"17","author":"Pentek","year":"2016","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.ymgme.2026.109734_bb0120","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/jpen.2317","article-title":"Impact of infusion frequency on quality of life in patients receiving home parenteral nutrition","volume":"46","author":"Stanner","year":"2022","journal-title":"JPEN J. Parenter. Enteral Nutr."},{"key":"10.1016\/j.ymgme.2026.109734_bb0125","first-page":"85","article-title":"Home infusion program with enzyme replacement therapy for Fabry disease: the experience of a large Italian collaborative group","volume":"12","author":"Concolino","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2026.109734_bb0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","article-title":"Quality of life in patients with Fabry disease: a systematic review of the literature","volume":"10","author":"Arends","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.109734_bb0135","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V82.4.1107.1107","article-title":"Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients","volume":"82","author":"Zimran","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2026.109734_bb0140","doi-asserted-by":"crossref","first-page":"330","DOI":"10.12968\/bjon.2006.15.6.20681","article-title":"Intravenous enzyme replacement therapy: better in home or hospital?","volume":"15","author":"Milligan","year":"2006","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.ymgme.2026.109734_bb0145","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ymgme.2009.04.007","article-title":"Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidoses","volume":"97","author":"Burton","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109734_bb0150","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10545-008-0980-0","article-title":"Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively","volume":"31","author":"Bagewadi","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.109734_bb0155","article-title":"Impact of the COVID-19 pandemic on the standard of care for patients with lysosomal storage diseases: a survey of healthcare professionals in the Fabry, Gaucher, and Hunter Outcome Survey registries","volume":"28","author":"Elstein","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2026.109734_bb0160","first-page":"86","article-title":"Impact of COVID-19 pandemic on chronic diseases care follow-up and current perspectives in low resource settings: a narrative review","volume":"13","author":"Fekadu","year":"2021","journal-title":"Int. J. Physiol. Pathophysiol. Pharmacol."},{"key":"10.1016\/j.ymgme.2026.109734_bb0165","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2011.02.018","article-title":"Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS)","volume":"103","author":"Burton","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.109734_bb0170","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/gim.2013.162","article-title":"A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy","volume":"16","author":"Giugliani","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2026.109734_bb0175","doi-asserted-by":"crossref","first-page":"1384, 1386","DOI":"10.12968\/bjon.2007.16.22.27768","article-title":"Home therapy for lysosomal storage disorders","volume":"16","author":"Hughes","year":"2007","journal-title":"Br. J. Nurs."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671922600017X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671922600017X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:10:42Z","timestamp":1777608642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109671922600017X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S109671922600017X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.109734","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety profile of idursulfase administered at home in patients with mucopolysaccharidosis II enrolled in the Hunter Outcome Survey","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.109734","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Takeda Pharmaceuticals International AG. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109734"}}